SARM1 Inhibitors Market by Target Indications, Type of Molecules, Drug Developers, Drug Candidates and Key Geographies: Industry Trends and Global Forecasts, 2022-2040

Neurological disorders are considered the second leading cause of death and the primary cause of long-term disability, worldwide. Across the globe, over 6.5 million neurological disorder related deaths are reported annually. Further, according to a report published by the United Nations (UN), close to 1 billion people, globally, suffer from various types of neurological disorders. The growing number of patients suffering from neurodegenerative disorders has imposed a huge burden, in terms of finances as well as resources, on the overall healthcare system. In fact, the annual expenditure associated with neurological disorder care in 2020 was more than USD 655 billion, in the US alone. Given the fact that majority of the current treatment options have proven to be inadequate, especially for axonal degeneration associated neurological disorders, there is a high demand for highly effective therapeutics targeting neurological disorders. Interestingly, Sterile Alpha and toll / Interleukin-1 Receptor Motif-Containing 1 (SARM1), an NADase enzyme, has been found to play a critical role in inducing axonal degeneration, which is a central pathological feature in various neurodegenerative disorders.

Presently, several industry and non-industry stakeholders are evaluating SARM1 inhibitors as potential therapeutic agents for the treatment of neurological disorders, such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and multiple sclerosis across various preclinical studies and early stages of clinical development, worldwide. Given the encouraging research outcomes, the players in this domain have received more than USD 10 million in grants, since 2014, from the various private and public organizations. Additionally, several patents related to SARM1 inhibitors have been recently filed / granted, demonstrating the continued innovation in this domain. Driven by the ongoing pace of innovation in this field, increasing R&D activity and promising pre-clinical data, several promising leads are anticipated to be commercially launched over the coming decade and SARM1 inhibitors market is anticipated to witness substantial growth in the mid to long-term.

Scope of the Report

The ‘SARM1 Inhibitors Therapeutics Market by Target Indications (Multiple Sclerosis, Peripheral, Central and Ocular Nervous System Disorders, Peripheral Neuropathies, Glaucoma and Amyotrophic Lateral Sclerosis), Type of Molecule (Small Molecules and Biologics), Drug Developers, Drug Candidates and Key Geographical Regions (North America and Europe): Industry Trends and Global Forecasts, 2022-2035’ report features an extensive study of the current landscape, offering an informed opinion on the likely adoption of SARM1 inhibitors therapeutics in the healthcare domain, till 2040. The report features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this market space. Amongst other elements, the report includes:

• A brief introduction to SARM1 inhibitors therapeutics, featuring information on role of SARM1 pathway in neurodegenerative disorders, mechanism of action of SARM1, along with mechanism of SARM1 pathway inhibition. This chapter further features details related to the recent advancements and future prospects in this domain.
• A detailed overview of the current market landscape of SARM1 inhibitors therapeutics that are currently being researched in pre-clinical studies, featuring an elaborate analysis of such therapies based on several relevant parameters, such as phase of development (preclinical and discovery), type of molecule (small molecules and biologics), target indication (unspecified neurological disorders, amyotrophic lateral sclerosis, multiple sclerosis, peripheral neuropathies, glaucoma and peripheral, central and ocular nervous system disorders) and type of developers (industry and non-industry). In addition, it provides details on the SARM1 inhibitors therapeutic developers, along with analyses based on their year of establishment, company size, leading players (in terms of number of SARM1 inhibitors candidates) and geographical location of the players.
• An insightful company competitiveness analysis of SARM1 inhibitors therapeutic developers (industry and non-industry players), taking into consideration supplier strength (based on company’s experience in this field) and company competitiveness (based on phase of development, target indications and type of molecule).
• Elaborate profiles of prominent players that are engaged in evaluating SARM1 inhibitors therapeutics, featuring a brief overview of the company, along with information on product portfolio, patent portfolio, recent developments and an informed future outlook.
• A detailed analysis of more than 120 peer-reviewed, scientific articles related to research on SARM1 inhibitors therapeutics, over last 12 years, based on several relevant parameters, such as year of publication, type of publication, most popular journals, popular keywords, most active publishers, most popular affiliations and distribution by geography.
• An in-depth analysis on various grants, received since the year 2014, by players engaged in this field based on year of award, support period, amount awarded, funding institute, type of grant application, activity code, type of study section, purpose of grant, prominent program officers, recipient organizations, popular NIH departments and location of recipient organizations.
• An in-depth analysis of the various patents that have been filed / granted related to SARM1 inhibitors therapeutics, till 2022, taking into consideration several relevant parameters, such as type of patent, publication year, application year, geographical region, CPC symbols, type of applicant, key focus area, patent age and leading players (in terms of size of intellectual property portfolio). It also features a patent benchmarking analysis and a detailed patent characteristics and patent valuation analysis.
• Information on recent developments (partnerships and collaborations, and funding and investments) reported by several players engaged in the SARM1 inhibitors therapeutics domain.
• A detailed market forecast analysis, highlighting the likely growth of the SARM1 inhibitors therapeutics in the healthcare market, over the period 2022-2040, based on several relevant parameters, such as target patient population, likely launch year of therapy candidates, approval timeline of drugs, likely price points and expected rates of adoption, across various geographical regions. The report also features the likely distribution of the current and forecasted opportunity related to SARM1 inhibitors therapeutics market across type of molecule (small molecules and biologics), target indication (multiple sclerosis, peripheral, central and ocular nervous system disorders, peripheral neuropathies, glaucoma and amyotrophic lateral sclerosis), drug developers, drug candidates and key geographical regions (North America and Europe).

Frequently Asked Questions

• Who are the leading players engaged in the development of SARM1 inhibitors therapeutics?
• What is the evolving trend of publications focused on SARM1 inhibitors therapeutics?
• How is the intellectual property landscape in this field likely to evolve in the foreseen future?
• What are the recent developments and strategic initiatives undertaken by players engaged in this market space related to research and development of SARM1 inhibitors therapeutics? 
• What are the key value drivers that are likely to influence the evolution of this upcoming market?
• How is the current and future market opportunity likely to be distributed across key market segments?